Promising Drug for chronic myeloid leukemia Fast tracked by FDA

ChemGenex Pharmaceuticals chief executive Dr Greg Collier said the drug, omacetaxine, offered significant potential because it killed the stem cells that caused chronic myeloid leukemia (CML). Dr Collier said 80 per cent of patients on the clinical trials conducted in Australia, the US and Europe, no longer had cancer in the blood and one in five no longer had cancer in the bone marrow.

International clinical trials confirm omacetaxine significantly increases the survival rates of patients. The drug may be available within months. "This is exciting because it targets those patients who have no other options," Dr Collier said. ChemGenex said the drug was in final clinical trials and the company was hopeful of approval by the US regulators the Food and Drug Administration early next year. The FDA has granted fast-track status to omacetaxine because the drug is the only treatment available to CML patients with a specific gene mutation.

Blog Category: 

More Articles

More Articles

Amazon.com is pleased to have the Lymphoma Information Network in the family of Amazon.com associates. We've agreed to ship items...

The question ought to be what are myelodysplastic syndromes (MDS), since this is a group of similar blood and bone marrow diseases that...

Merkel Cell Carcinoma (MCC) is a very rare and aggressive skin cancer that usually develops when a person is in his or her 70s. It is...

Radiation Therapy Topics

...

At some point, the Seattle biotech company Cell Therapeutics Inc (CTI) should earn an entry in the Guinness Book of World Records for utter and...

Site Beginnings

This site was started as Lymphoma Resource Page(s) in 1994. The site was designed to collect lymphoma...

Three papers appearing in the journal Blood and pointing towards a regulator-suppressor pill could offer hope to blood cancer...

The US Food and Drug Administration (FDA) has granted a third so-called Breakthrough Therapy Designation for the investigational oral...

The US Food and Drug Administration today has approved an expanded use of Imbruvica (ibrutinib) in patients with...

The U.S. Food and Drug Administration has announced that it has granted "Breakthrough Therapy Designation" for the investigational agent...

According to a new study published in the Proceedings of the National Academy of Sciences, a team from the University of California, San...

Pharmacyclics has announced that the company has submitted a New Drug Application (NDA) to the US Food and Drug Administration (FDA) for...

New research suggests that frontline radioimmunotherapy...

Gilead Sciences has announced results of the company's Phase II study of its investigational compound idelalisib, an oral inhibitor of...

Sitemap